Extrawell Pharmaceutical Holdings (HKSE:00858) Accounts Receivable : HK$6.11 Mil (As of Sep. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Extrawell Pharmaceutical Holdings's accounts receivables for the quarter that ended in Sep. 2023 was HK$6.11 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Extrawell Pharmaceutical Holdings's Days Sales Outstanding for the quarter that ended in Sep. 2023 was 36.99.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Extrawell Pharmaceutical Holdings's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was HK$-0.03.

Extrawell Pharmaceutical Holdings Accounts Receivable Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings Accounts Receivable Chart

Extrawell Pharmaceutical Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Accounts Receivable

Get a 7-Day Free Trial

18.56

9.66

8.00

7.18

5.80

Extrawell Pharmaceutical Holdings Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Accounts Receivable	Get a 7-Day Free Trial															9.76	7.18	7.77	5.80	6.11

Extrawell Pharmaceutical Holdings Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Extrawell Pharmaceutical Holdings Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Extrawell Pharmaceutical Holdings's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	6.109	/	30.141	*	91
=	36.99

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Extrawell Pharmaceutical Holdings's accounts receivable are only considered to be worth 75% of book value:

Extrawell Pharmaceutical Holdings's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(91.499	+	0.75 * 6.109	+	0.5 * 5.564	-	165.651
-	0	-	-1.176)	/	2390
=	-0.03

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Extrawell Pharmaceutical Holdings Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » Accounts Receivable

Traded in Other Exchanges

N/A

Address

979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG

Website

http://www.extrawell.com.hk

Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.

Executives

Mao Yumin	2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited	2201 Interest of corporation controlled by you
Ease Gold Investments Limited	2201 Interest of corporation controlled by you
Jnj Investments Ltd	2201 Interest of corporation controlled by you
United Gene Group Ltd	2201 Interest of corporation controlled by you
United Gene Holdings Limited	2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited	2101 Beneficial owner
Xie Yi	2201 Interest of corporation controlled by you
Huang Zhenping	2101 Beneficial owner
United Gene Industry Group Limited	2101 Beneficial owner
Chen Xuhua	2202 Interest of your spouse
Cheng Yong	2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines